Retrospective Study
Copyright ©The Author(s) 2025.
World J Clin Oncol. Apr 24, 2025; 16(4): 102199
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.102199
Table 2 Clinical efficacy of anlotinib combined with nab-ptx in second-line or above treatment for advanced gastric cancer
Clinical efficacy
Patient No.
Proportion (%)
Complete response00
Partial response1644.44 (16/36)
Stable response1233.33 (12/36)
Progressive disease822.23 (8/36)
Objective response44.44
Median PFS6.0 months
Disease control rate77.78
Median OS12.0 months